doi: 10.1016/s1471-4906(02)02263-9.
New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells
- PMID: 12133793
- DOI: 10.1016/s1471-4906(02)02263-9
Item in Clipboard
New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells
Trends Immunol.
2002 Aug.
Abstract
Since the discovery of 4-1BB 15 years ago, the receptor and its ligand (4-1BBL) have remained enigmatic molecules because of their highly regulated pattern of expression. Classically, 4-1BB is known to function as a costimulator for T cells and as a potent survival factor for CD8+ T cells. Recent studies highlight the participation of 4-1BB and its ligand 4-1BBL in a more complex network of immune cell responses and suggest that intervening in the 4-1BB costimulatory pathway might have some potential as a therapeutic approach to immune disorders.
Similar articles
-
4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells.Int Immunol. 2002 Oct;14(10):1155-67. doi: 10.1093/intimm/dxf080. Int Immunol. 2002. PMID: 12356681
-
A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo.J Immunol. 2004 Jan 15;172(2):981-8. doi: 10.4049/jimmunol.172.2.981. J Immunol. 2004. PMID: 14707071
-
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells.Int Immunol. 2002 Mar;14(3):275-86. doi: 10.1093/intimm/14.3.275. Int Immunol. 2002. PMID: 11867564
-
Role of 4-1BB:4-1BB ligand in cancer immunotherapy.Cancer Gene Ther. 2004 Mar;11(3):215-26. doi: 10.1038/sj.cgt.7700670. Cancer Gene Ther. 2004. PMID: 14671675 Review.
-
Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9. Arch Immunol Ther Exp (Warsz). 1999. PMID: 10604232 Review.
Cited by
-
Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.Clin Dev Immunol. 2013;2013:450291. doi: 10.1155/2013/450291. Epub 2013 Mar 7. Clin Dev Immunol. 2013. PMID: 23533456 Free PMC article. Review.
-
KLF2 inhibition expands tumor-resident T cells and enhances tumor immunity.Res Sq [Preprint]. 2025 Mar 13:rs.3.rs-5966555. doi: 10.21203/rs.3.rs-5966555/v1. Res Sq. 2025. PMID: 40162209 Free PMC article. Preprint.
-
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.Oncoimmunology. 2013 Jan 1;2(1):e22837. doi: 10.4161/onci.22837. Oncoimmunology. 2013. PMID: 23482891 Free PMC article.
-
B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.Exp Hematol. 2007 Mar;35(3):443-53. doi: 10.1016/j.exphem.2006.11.002. Exp Hematol. 2007. PMID: 17309825 Free PMC article.
-
T Cells in Adipose Tissue: Critical Players in Immunometabolism.Front Immunol. 2018 Oct 30;9:2509. doi: 10.3389/fimmu.2018.02509. eCollection 2018. Front Immunol. 2018. PMID: 30459770 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
